AI Innovation and Strategic DAM Deployments Fuel Record First Half for Bynder

24.7.2024 16:00:00 EEST | Business Wire | Press release

Bynder, a global leader in enterprise digital asset management (DAM), has revealed how the accelerated adoption of the company’s AI-powered solutions and strategic DAM deployments have driven record growth in the first half of 2024.

More than 350 customers have adopted Bynder’s enhanced AI Search Experience since its launch nine months ago, and through the solution, more than 30 million images have been processed. Bynder, which currently has over 150 million active assets on its platform, also reported that in the first half of the year, it has seen a 20% year-on-year increase in the delivery of assets to connected systems. With assets delivered 113 billion times in the first half of the year, this shows that Bynder’s customers are continuing to leverage content as a strategic differentiator to deliver exceptional content experiences.

Bynder first integrated AI into its platform in 2016, demonstrating the company’s long-term commitment well before it became mainstream. Since then, Bynder has accelerated its efforts by acquiring an AI company and launching AI Search Experience, continually enhancing its AI capabilities and giving customers governance and control over how AI is used in their organizations and on their own terms.

Since the launch of Bynder’s AI Search Experience, many of Bynder's customers have adopted the solution, reinforcing the trend that AI is increasingly viewed as a strategic tool for marketers seeking to streamline content operations and improve customer experience. This trend validates Bynder's approach to AI, demonstrating the need to harness AI responsibly to deliver tangible benefits to its customers.

Bynder’s AI-powered DAM platform is pivotal in supporting go-to-market operations and the adoption of AI within content operations has driven the rapid uptake of Bynder’s AI Search Experience. This solution is customer-inspired and enables teams to maximize asset reuse, save resources, reduce time spent searching for assets, and automatically eliminate duplicates.

The benefits of the solution were evidenced at Bynder’s recent customer Spotlight Awards where brands such as Viator, Les Mills and Inspire Brands were recognized for their excellence in innovation, creating compelling value and return on investment when it comes to the implementation and use of Bynder DAM.

By leveraging AI-powered recommendations and filtering options, Inspire Brands was able to quickly locate and distribute relevant assets across its portfolio of sub-brands. This new level of findability has promoted content reuse within the organization and increased the value of the assets that the company invests in.

Cliff Crosbie, Head of AI Strategies at Bynder, said: “It’s great to see that our ongoing innovation and market leadership in AI has continued to drive growth in the first half of this year, along with our strategic DAM deployments which have both become invaluable solutions for our customers. The digital landscape continues to evolve faster than ever, so it’s our aim to implement AI responsibly to help drive scale and efficiency and we’re looking forward to bringing the next phase of our AI enhancements to market very soon.”

As a result of the company’s accelerated growth, Bynder has appointed Ann-Michèle Verheyden as its new Chief Legal Officer. Ann-Michèle brings extensive experience in SaaS, IP and privacy, supporting Bynder’s position and investment in AI where she will be building a robust compliance framework enabling businesses to navigate the complexities of AI-driven technology while mitigating risk.

Richard Heitmann also joins Bynder as its new Chief Marketing Officer. Richard brings a wealth of experience from high-growth startups like Aspera and enterprise software experience from IBM. Richard’s expertise will help drive further growth and bring Bynder’s platform innovations to the market.

Looking forward to the second half of the year, Bynder will host its inaugural customer event, Bynder Connect, in September in Amsterdam. The event will bring together industry leaders to share insights, launch new innovations, and celebrate successes with its customers.

For more information on Bynder’s AI-powered DAM, please visit: https://www.bynder.com/en/solutions/initiatives/ai-automation/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724434819/en/

Contacts

Manisha Mehta / manisha.mehta@bynder.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom